Principal Financial Group
ATOS icon

Principal Financial Group’s Atossa Therapeutics ATOS Stock Holding History

Principal Financial Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-683
Closed -$15.6K – 2213
2024
Q3 		$15.6K Sell
683
-197
-22% -$3.98K ﹤0.01% 2213
2024
Q2 		$15.7K Buy
+880
New +$19.5K ﹤0.01% 2350
2022
Q4 		– Sell
-976
Closed -$12K – 2450
2022
Q3 		$12K Buy
976
+29
+3% +$421 ﹤0.01% 2476
2022
Q2 		$15K Sell
947
-688
-42% -$10.8K ﹤0.01% 2500
2022
Q1 		$31K Sell
1,635
-115
-7% -$2.34K ﹤0.01% 2506
2021
Q4 		$42K Buy
1,750
+1,033
+144% +$37.8K ﹤0.01% 2489
2021
Q3 		$35K Sell
717
-207
-22% -$12K ﹤0.01% 2548
2021
Q2 		$88K Buy
+924
New +$48.9K ﹤0.01% 2545

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Principal Financial Group's ATOS Position: Q4 2024 in Review

Principal Financial Group sold out of Atossa Therapeutics (ATOS) in Q4 2024, closing a stake of 683 shares — an estimated $15.6K sold.

Principal Financial Group first reported a position in ATOS in Q2 2021 and held it in 8 quarters. The position peaked at $88K in Q2 2021. 86 funds tracked by Wall St. Rank hold ATOS as of Q4 2024.

  • Principal Financial Group reported no remaining Atossa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Principal Financial Group sold 683 Atossa Therapeutics shares in Q4 2024, an estimated $15.6K.
  • Principal Financial Group first reported a position in Atossa Therapeutics in Q2 2021 and held it in 8 quarters.
  • Principal Financial Group's Atossa Therapeutics position peaked at $88K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2024.

Based on Principal Financial Group's 13F filing for Q4 2024, filed 31 Jan 2025.